Rubicon Research (RUBICON)

FairStock Score: 56/100 — STEADY

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Rubicon Research as a fast-growing pharma business, but I must separate a wonderful business from a wonderful price. At ₹1,619.10, the market values it at ₹26,730 Cr. It earns a P/E of 92.57 and trades at 20.74 times book value of ₹78.07. That is not a Graham bargain; it is a growth premium. Yet the operating numbers are impressive: ROE 26.97%, ROCE 26.05%, debt/equity only 0.24, and Piotroski F-Score 7/9. Sales growth of 43.50% and profit growth of 96.70% show strong momentum. The latest quarter had ₹476 Cr sales and ₹73 Cr net profit, while free cash flow was ₹94 Cr. Five-year revenue CAGR of 37.32% is exceptional. Promoter holding of 59.99% gives skin in the game. PEG ratio of 1.07 suggests that if this growth continues, the P/E is not absurd. FairStock score 55/100 STEADY confirms neither a clear bargain nor a broken business. The high ROCE hints at some competitive advantage, but I cannot verify a durable moat from these figures alone. My concern is the valuation and tiny dividend yield of 0.09%; much future success is already discounted. The 52-week range ₹570.75–₹1,875.30 shows Mr. Market can be violently optimistic and pessimistic. I would want a margin of safety, not chase near highs. Watch whether profit growth converts into free cash flow, whether ROE/ROCE stays above 20%, and whether sales growth sustains. Rubicon is a quality fast grower, but at this price I’d put it on a watchlist, not buy aggressively.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer